Skip to main content

The first compact and easy-to-use microreactor device for Body-On-Chip experiments.

Periodic Reporting for period 1 - B-On-Chip (The first compact and easy-to-use microreactor device for Body-On-Chip experiments.)

Reporting period: 2017-01-01 to 2017-05-31

BEOnChip S.L. is a leading company focused on the field of Micro-biotechnology. We count on a patent portfolio of microfluidic chips to be used as organ-on-chips that can be defined as micro-sized artificial organs with the unique ability to host different cells to mimic human-type responses to new drugs. Now, in the B-On-Chip project we seek bringing to the market the first compact, fully automated and easy-to-use device to link multiple organs-on-chip, enabling the so-called body-on-chip experiments. The use of B-On-Chip by the Pharma industry has the potential to reduce the use of laboratory animals, to accelerate drug development and to study how reactions in one organ affect another. Therefore, B-On-Chip will offer the most accurate in vitro data on new drug efficiency, security, and toxicity in a fast, automatic and reliable way.


F.0.1-To search for and identify potential suppliers of Microreactor technology components in EU.
F.0.2- To build up a work plan for final technology development: key milestones, tasks and risk analysis.
F.0.3-To search for and identify potential distributors in EU and define our commercialization strategy
F.0.4-To define our IP strategy and perform a patentability analysis.
F.0.5-To perform a market analysis to define the best channels for entering different geographic markets.
F.0.6- Preparation of a business plan for the next 5 years.
The work performed and the main achievements have been the following:
 We have performed an in-depth research of all companies dedicated to supply, develop and manufacture components for microfluidic technology
 We have defined a precise 2-years work plan for technology development together with a risk management plan.
 We have performed a careful analysis of distributors.
 We have performed a patentability and freedom to operate analysis.
 We have performed an exhaustive market research study.
The B-on-Chip project will not only benefit the pharmaceutical industry allowing them to reduce the long time and huge costs required for new drugs development, but it will also allow: 1) developing new, cheaper and more efficient drugs, 2) developing new biomarkers for diagnosis. All this will lead to a better quality of life for patients and life expectancy, the reduction of expenses by healthcare system.